Approval · Notice of Compliance 34587 · 2024
STRENSIQ: Notice of Compliance 34587
Issued December 18, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34587
- Date
- December 18, 2024
- Company
- Alexion Pharma GmbhBaar, Switzerland
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Modifications in drug substance manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| STRENSIQ | Not yet assigned | — |
Medicinal ingredients
- ASFOTASE ALFA 12 MG per 0.3ML
- ASFOTASE ALFA 18 MG per 0.45ML
- ASFOTASE ALFA 28 MG per 0.7ML
- ASFOTASE ALFA 40 MG per ML
- ASFOTASE ALFA 80 MG per 0.8ML